Solid colloidal drug delivery systems: Nanoparticles

doi:10.1016/0378-5173(81)90100-9

International Journal of Pharmaceutics

Volume 8, Issue 3, May 1981, Pages 217-234

https://doi.org/10.1016/0378-5173(81)90100-9 Get rights and content

Abstract

After outlining the criteria of an ideal solid colloidal drug delivery system, a review is made under 5 headings of the various systems described in the literature. None of these systems are ideal. The problems of maximizing the drug content of the solid system are discussed. Viruses and vaccines, diagnostic agents, cytotoxics, flukicides and antiarthritics are given as examples of the drugs that may be incorporated into these so-called nanoparticles. The biggest barrier to successful exploitation of nanoparticles to minimize rapid hepatic clearance.

References (69)

N.L. Astorri et al.
Comparative study of the immediate action of L-2,3,5,6-tetrahydrophenylimido(2,1b)-azothiazol (Levamisole) and its dextroisomer on the phagocytosis of radiogold colloids
Int. J. Nucl. Med. Biol.
(1979)
G. Birrenbach et al.
Polymerized micelles and their use as adjuvants in immunology
J. Pharm. Sci.
(1976)
J.C. Boylan et al.
Molecular-scale drug entrapment as a precise method of controlled drug release. IV: Entrapment of anionic drugs by polymeric gelation
J. Pharm. Sci.
(1973)
P. Couvreur et al.
Nanocapsules: a new type of lysosomotropic carriei
FEBS Lett.
(1977)
P. Couvreur et al.
Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum
J. Pharm. Sci.
(1979)
P. Couvreur et al.
Tissue distribution of antiuimour drugs associated with polyalkylcyanoacrylate nanoparticles
J. Pharm. Sci.
(1980)
G.P. D'Onofrio et al.
Encapsulated microcapsules
Int. J. Pharm.
(1979)
P. Edman et al.
Immobilization of proteins in microspheres of biodegradable polyacryldextran
J. Pharm. Sci.
(1980)
B. Ekman et al.
Improved stability of proteins immobilized in microparticles prepared by a modified emulsion polymerization technique
J. Pharm. Sci.
(1978)
R.M. Fitch et al.
Acrylate polymer colloids: kinetics of autocatalysed hydrolysis
J.Coll. Int. Sci.
(1979)

G. Gregoriadis et al.

Fate of a liposome-associatcd agent injected into normal and tumour-bearing rodents. Attempts to improve localization in tumour tissues

Life. Sci.

(1977)

J. Gruenberg et al.

Interactions of liposomes with Trypanosoma Brucei plasma membrane

Biochem. Biophys. Res. Comm.

(1979)

M. Kanke et al.

Clearance of ¹⁴¹Ce-labelled microspheres from blood and distribution in specific organs following intraveous and intraarterial administration in beagle dogs

J. Pharm. Sci.

(1980)

P.A. Kramer

Albumin microspheres as vehicles for achieving specificity in drug delivery

J. Pharm. Sci.

(1974)

J. Kreuter et al.

Distribution and elimination of poly(methyl-2-¹⁴C-methacrylate) nanoparticle radioactivity after injection in rats and mice

J. Pharm. Sci.

(1979)

E.A. Peterson et al.

Reversible, field induced agglomeration in magnetic colloids

J. Coll. Int. Sci.

(1977)

F.M. Richards et al.

Glutaraldehyde as a protein cross-linking reagent

J. Mol. Biol.

(1968)

S.G. Schulman

Fundamentals of interaction of ionizing radiations with chemical, biochemical and pharmaceutical systems

J. Pharm. Sci.

(1973)

T.L. Smith et al.

Intrinsic viscosities and other theological properties of flocculated suspensions of nonmagnetic and magnetic ferric oxides

J. Coll. Int. Sci.

(1979)

K. Widder et al.

Magnetic microspheres: synthesis of a novel parenteral drug carrier

J. Pharm. Sci.

(1979)

D. Allan et al.

The isolation and characterization of 60 nm vesicles (nanovesicies) produced during ionophore A23187-induced budding of human erythrocytes

Biochem. J.

(1980)

H.L. Atkins et al.

Adverse reactions to radiopharmaceuticals

J. Nucl. Med.

(1972)

Birrenbach, G., Micellepolymerization, possible inclusion of compounds (nanoencapsulation) and their suitability as...

C.C. Boag

Organ directive drug delivery systems

M. Pharm. thesis Victoria Institute of Colleges

(1979)

Boag, C.C., Oppenheim, R.C., Montague, P. and Birchall, G.R., The manufacture and in vivo testing of nanoparticles...

J.W.B. Bradfield et al.

The relative importance of blood flow and liver phagocytic function in the distribution of Technetium-^99m sulfur colloid

J. Nucl. Med.

(1977)

P. Couvreur et al.

Polycyanoacrylate nanocapsulles as potential lysosomotropic carriers: preparation, morphological and sorptive properties

J. Pharm. Pharmacol.

(1979)

P. Couvreur et al.

Les vecteurs lysosomotropes

J. Pharm. Bel.

(1980)

E.O. Dillingham et al.

Biological evaluation of polymers. I. Poly(methylmethacrylate)

J. Biomed. Mater. Res.

(1975)

B. Ekman et al.

Incorporation of macromolecules in microparticles: preparation and characteristics

Biochemistry

(1976)

B. Ekman et al.

Use of macromolecules in microparticles

Nature (London)

(1975)

J. Fielitz et al.

Strahlenbehandlung von medizinischen Artikeln und Verpackungsmaterialien

(1979)

M.J. Groves

The determination of size characteristics of sub-micrometre paiticulate systems

Pharm. Int.

(1980)

K. Gurny et al.

A new biocompatible drug delivery system for chronic implantation in animal brain

Pharm. Acta Helv.

(1979)

Cited by (83)

In vivo nano-biosensing element of red blood cell-mediated delivery
2021, Biosensors and Bioelectronics
Citation Excerpt :
Meanwhile, along with the rapid development of smart theranostic nanomaterial-based biosensors, emerging the problem of how to improve the positioning and circulation effectiveness of in vivo biosensing elements, as the accurate, stable, and long-term perception and transmission of diagnostic/therapeutic signals from targeted sites, as well as the controlled drug delivery to the selected positions are main factors decisively affect the clinical applications of nanobiosensors. The idea of beneficially influencing the bio-distribution and pharmacokinetics of the administrated drugs and sensing elements has led to the origination of drug delivery systems (DDSs), which include the concepts of temporal (i.e., rate of release) and spatial (i.e., site of release) control of the pharmacokinetic parameters of administrated agents by integrating them with other chemicals, administration devices or processes (Oppenheim, 1981). As early as the 1970s, it has been realized that in addition to the administration, the therapeutic effects and the long-term efficiency of continuous in vivo biosensing is determined by the attainment of an active drug and the functioning biosensing element with an appropriate concentration in the target site of the organism (Juliano, 1978).
Biosensors based on nanotechnology are developing rapidly and are widely applied in many fields including biomedicine, environmental monitoring, national defense and analytical chemistry, and have achieved vital positions in these fields. Novel nano-materials are intensively developed and manufactured for potential biosensing and theranostic applications while lacking comprehensive assessment of their potential health risks. The integration of diagnostic in vivo biosensors and the DDSs for delivery of therapeutic drugs holds an enormous potential in next-generation theranostic platforms. Controllable, precise, and safe delivery of diagnostic biosensing devices and therapeutic agents to the target tissues, organs, or cells is an important determinant in developing advanced nanobiosensor-based theranostic platforms. Particularly, inspired by the comprehensive biological investigations on the red blood cells (RBCs), advanced strategies of RBC-mediated in vivo delivery have been developed rapidly and are currently in different stages of transforming from research and design to pre-clinical and clinical investigations. In this review, the RBC-mediated delivery of in vivo nanobiosensors for applications of bio-imaging at the single-cell level, advanced medical diagnostics, and analytical detection of biomolecules and cellular activities are presented. A comprehensive perspective of the technical framework of the state-of-the-art RBC-mediated delivery systems is explained in detail to inspire the design and implementation of advanced nanobiosensor-based theranostic platforms taking advantage of RBC-delivery modalities.
Carbohydrate and protein based biopolymeric nanoparticles: Current status and biotechnological applications
2020, International Journal of Biological Macromolecules
Citation Excerpt :
Beyond the chemically synthesized nanoparticles, polymer of biological origin offers viable route due to its different and unique characteristics such as biocompatibility, biodegradability and ease of preparation methods. More studies have been done in the area of drug delivery using the biopolymeric nanoparticles [3]. Drug efficiency and its targeting capacity are increased with the use of biopolymers [4].
Wide sustainability and reusability of biomacromolecules such as carbohydrates and proteins-based biopolymers pave the way for providing maximal importance in the field of generating biopolymeric nanoparticles. As compared to synthetic nanomaterials, carbohydrate and protein based biopolymeric nanomaterials offer unique advantages that include antibacterial, biocompatible, immunogenicity, and biodegradable properties. Additionally, they have the significant property of more size distribution. Carbohydrate nanoparticles are primarily derived from the polysaccharide biopolymers such as alginate and chitosan; and protein nanoparticles are made from the diverse peptide biopolymers such as albumin, keratin, sericin, fibroin, gelatin and collagen. Advanced methods such as emulsification, desolvation, electrohydrodynamic atomization and coacervation are employed for the controlled fabrication of green biomacromolecules based nanoparticles. Suitability of biopolymeric nanoparticles in plethora of biotechnological applications are quite feasible with the advent of advanced technologies such as dynamic light scattering, scanning electron microscopy, transmission electron microscopy, atomic force microscopy, X-ray diffraction, Fourier transform infrared spectroscopy, and UV visible spectroscopy etc. Applications of such biomacromolecules nanoparticles are highly prevalent in agriculture, food, and biomedical industries. Thus, contributions of biopolymeric nanoparticles derived from carbohydrates and proteins biomacromolecules and their recent trends of patents granted in the biotechnological applications are critically discussed along with a promising future scope.
Core-shell biopolymer nanoparticles
2020, Biopolymer-Based Formulations: Biomedical and Food Applications
Among the available potential nanocarrier systems, biopolymer-based core–shell nanoparticles are particularly interesting. This interest is mainly because of the availability of large number of natural biopolymers, their unique physical properties including self-assembly, excellent interfacial properties and binding ability, and their high biocompatibility. Various types of food biopolymers including proteins, polysaccharides, lipids, and their combinations have been used to fabricate these nanocarriers. In this chapter, the different types of core–shell nanoparticles, current fabrication methods, and also their utilizations as delivery systems of small molecules, proteins, and nucleic acids have been reviewed. Major challenges of their utilizations in food and pharmaceutical applications are also spotlighted.
Nanoengineered biomaterials for retinal repair
2018, Nanoengineered Biomaterials for Regenerative Medicine
The retina is an important part of our central nervous system, and specifically, it receives light and converts it into neural signals, which are then relayed to the brain for visual processing. Furthermore, it is involved in circadian rhythms, helping regulate our sleep-wake cycle. Because of the highly metabolic nature of the retina, it can be damaged easily, resulting in a detrimental effect on daily activities. Retinal diseases, such as age-related macular degeneration and diabetic retinopathy, are the leading cause of blindness worldwide. Therapies target cellular and molecular mechanisms of these diseases but may not lead to substantial recovery of vision. Conventional therapeutic strategies are not always effective, and many patients do not recover full visual function. Nanoengineering technologies can be used in conjugation with cell-, drug-, or gene-based approaches to develop novel strategies for clinical use. In this chapter, we provide an overview of drug-, cell-, and gene-based therapies coupled with polymeric scaffolds to improve experimental strategies for retinal tissue engineering and repair. Both natural and synthetic polymers are extensively studied with the aim of their eventual use in clinical environments. Current clinical trials are summarized at the end of the chapter to raise interest in how nanoengineering technologies may be used for retinal repair and rescue.
Nanoparticles: A Novel Approach to Target Tumors
2017, Nano- and Microscale Drug Delivery Systems: Design and Fabrication
In the modern era, human health is intimidated by various diseases, such as autoimmune diseases, neurological diseases, cardiovascular diseases, and cancer. The particle size of a drug plays a major role in the site specificity and drug distribution, especially to target tumors disease. Efforts to treat such chronic diseases by conventional therapeutic systems are marred with nonspecific biodistribution, less bioavailability, poor aqueous solubility, overall characteristics of drug and nontarget specificity that influences the high rate of side effects. Nanostructured drug delivery systems can facilitate enhancement of the pharmacological response of therapeutic agents by improving the pharmacokinetic and pharmacodynamic properties. Certainly, therapeutic nanostructured drug delivery systems are a novel approach to deliver a drug to produce greater pharmacological response. Furthermore, in the past two decades research studies proved that nanostructured drug delivery systems are vital and rapid-raising techniques in health-care systems. From monitoring the disease to treatment in molecular level, nanoparticles in various forms and conjugations (coated with iron oxide, gold, and proteins), nanopores, nanocapsules, quantum dots, fullerenes, nanotubes, nanorobotics, have been a mainstay of drug delivery systems. This chapter gives extensive ideas about materials, methods applied for the production of nanoparticles to target various diseases, and also how to deal with toxicity management in nanolaboratories.
Gold nanoparticles: Emerging paradigm for targeted drug delivery system
2013, Biotechnology Advances
Citation Excerpt :
As a result, the drug is localized to a greater degree on the targeted site while leaving surrounding tissues unaffected. The ideal drug delivery system delivers drug at rates finely tuned to the biological requirement of the body (Cunliffe et al., 2005; Oppenheim, 1981; Pfister and Hsieh, 1990). Due to their high specificity and efficacy, TDDS are the future in rational drug design and development.
The application of nanotechnology in medicine, known as nanomedicine, has introduced a plethora of nanoparticles of variable chemistry and design considerations for cancer diagnosis and treatment. One of the most important field is the design and development of pharmaceutical drugs, based on targeted drug delivery system (TDDS). Being inspired by physio-chemical properties of nanoparticles, TDDS are designed to safely reach their targets and specifically release their cargo at the site of disease for enhanced therapeutic effects, thereby increasing the drug tissue bioavailability. Nanoparticles have the advantage of targeting cancer by simply being accumulated and entrapped in cancer cells. However, even after rapid growth of nanotechnology in nanomedicine, designing an effective targeted drug delivery system is still a challenging task. In this review, we reveal the recent advances in drug delivery approach with a particular focus on gold nanoparticles. We seek to expound on how these nanomaterials communicate in the complex environment to reach the target site, and how to design the effective TDDS for complex environments and simultaneously monitor the toxicity on the basis of designing such delivery complexes. Hence, this review will shed light on the research, opportunities and challenges for engineering nanomaterials with cancer biology and medicine to develop effective TDDS for treatment of cancer.

View all citing articles on Scopus

View full text

Solid colloidal drug delivery systems: Nanoparticles

Abstract

Int. J. Nucl. Med. Biol.

J. Pharm. Sci.

J. Pharm. Sci.

FEBS Lett.

J. Pharm. Sci.

J. Pharm. Sci.

Int. J. Pharm.

J. Pharm. Sci.

J. Pharm. Sci.

J.Coll. Int. Sci.

Life. Sci.

Biochem. Biophys. Res. Comm.

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

J. Coll. Int. Sci.

J. Mol. Biol.

J. Pharm. Sci.

J. Coll. Int. Sci.

J. Pharm. Sci.

The isolation and characterization of 60 nm vesicles (nanovesicies) produced during ionophore A23187-induced budding of human erythrocytes

Biochem. J.

Adverse reactions to radiopharmaceuticals

J. Nucl. Med.

Organ directive drug delivery systems

M. Pharm. thesis Victoria Institute of Colleges

The relative importance of blood flow and liver phagocytic function in the distribution of Technetium-99m sulfur colloid

J. Nucl. Med.

Polycyanoacrylate nanocapsulles as potential lysosomotropic carriers: preparation, morphological and sorptive properties

J. Pharm. Pharmacol.

Les vecteurs lysosomotropes

J. Pharm. Bel.

Biological evaluation of polymers. I. Poly(methylmethacrylate)

J. Biomed. Mater. Res.

Incorporation of macromolecules in microparticles: preparation and characteristics

Biochemistry

Use of macromolecules in microparticles

Nature (London)

Strahlenbehandlung von medizinischen Artikeln und Verpackungsmaterialien

The determination of size characteristics of sub-micrometre paiticulate systems

Pharm. Int.

A new biocompatible drug delivery system for chronic implantation in animal brain

Pharm. Acta Helv.

The relative importance of blood flow and liver phagocytic function in the distribution of Technetium-^99m sulfur colloid